Malignant autosomal recessive (AR) osteopetrosis represents an absolute indication for bone marrow transplantation (BMT). Over the last 15 years, almost 100 BMTs for osteopetrosis have been reported. The median age at transplant of most patients is 4 months. Very few cases of mild AR osteopetrosis have been described. Here, we report the good outcome of two cases of mild AR osteopetrosis with a follow-up of 5 and 6 years, respectively, after an HLA-identical sibling transplant undergone at 5 and 12 years of age, respectively. At the time of BMT, severe visual impairment was present in both children. Bone biopsy demonstrated hypermineralization with virtual obliteration of the medullary spaces, rare microfoci of hematopoiesis and marked deficiency in osteoclastic activity. Successful engraftment was complicated by hypercalcemia, controlled by a combination of bisphosphonate, phosphate infusions, vigorous hydration and calcitonin. Following BMT, radiological and histological findings showed extensive bone resorption with marked augmentation of the osteoclasts in normalized marrow. No improvement was observed in visual acuity, despite complete remodeling of skeletal abnormalities. We conclude that allogeneic BMT is the only chance of curing mild AR osteopetrosis. Bone Marrow Transplantation (2000) 26, 219-224.
malignant form is characterized by severe clinical features appearing during the first decade of life or in fetal life, and by rapid development during the clinical course of fractures, anemia, granulocytopenia, thrombocytopenia and neurological problems (blindness, deafness, hydrocephalus). This form leads to death in the majority of cases within the first 5 years of life. A less severe autosomal recessive form has been described, with later onset and clinical features characterized by generalized osteopetrosis, short stature, macrocephaly, mandibular osteomyelitis, dental abnormalities and mild anemia. 4 The autosomal dominant form is usually diagnosed coincidentally in the young adult with multiple fractures, bone pain, cranial nerve palsy and osteomyelitis of the mandibular bone. 5 The fourth form is due to deficiency of carbonic anhydrase II. Clinical manifestations are pathologic fractures, renal tubular acidosis and cerebral calcifications. The inheritance pattern is autosomal recessive; many of these patients have mental retardation.
Metabolic balance studies have been performed in patients with osteopetrosis. Children with the malignant form may have a positive calcium and phosphorus balance, while in patients with benign recessive or dominant forms calcium and phosphorus concentrations are normal. Hypocalcemia has been observed in a few cases. Serum parathyroid hormone can be elevated in some hypocalcemic patients with malignant osteopetrosis. Children with carbonic anhydrase II deficiency have hyperchloremic acidosis, increased urinary pH and severe carbonic anhydrase II deficiency in erythrocytes.
Rare autosomal recessive cases have been reported with associated neuroaxonal dystrophy and osteopetrosis. These children have died after delivery or in the first months of life from acute bronchopneumonia. The autopsy revealed numerous neuroaxonal spheroids in the hippocampus, basal ganglia, pons, medulla, spinal cord and peripheral nerves with cerebral atrophy, ventricular dilation and absence of corpus callosum. 6 In the 1970s, Walker et al 7 demonstrated the hematopoietic origin of osteoclastic cells and the possibility of curing mutant animals by transplantation of hematopoietic stem cells. In man, the malignant recessive forms of osteopetrosis can also be successfully treated by allogeneic bone marrow transplantation. The median age at transplantation of most reported cases is 4 months. 7 Very few patients with mild AR osteopetrosis successfully grafted at an older age have been described. 8, 9 Here, we report good outcomes of two cases with a mild variant of AR osteopetrosis, with a follow-up of 5 and 6 years, respectively, after the BMTs they underwent at 5 and 12 years of age. Informed consent was obtained by parents, and the protocol was approved by the local Medical Ethics Committee.
Case 1

Clinical characteristics
IA was referred to our BMT unit at the age of 12 years with a diagnosis of osteopetrosis. Clinical characteristics at presentation and before BMT are summarized in Table 1 . At the time of our examination skeletal radiographs showed diffuse bone sclerosis, metaphyseal widening and absence of marrow cavity. Bone biopsy revealed a significant reduction of medullary spaces with a total absence of osteoclasts. Fundus examination revealed bilateral optic subatrophy with pale optic disks and narrowing of the retinal vessels. Visual field examination demonstrated a central scotoma in the right eye and a temporal quadrantanopsic defect in the left eye. Coronal magnetic resonance imaging (MRI) showed low signal intensity on both T1 and T2 weighted images in the regions of sclerotic bone and intermediate signal intensity in the areas containing bone marrow ( Figure 1a) . Absence of metabolic acidosis with alkaline pH of urine and cerebral calcifications excluded a CA II deficiency syndrome, while family history and severe clinical manifestations excluded a dominant pedigree. 
Bone marrow transplant
The patient was conditioned for BMT with busulphan (Bu) 16 mg/kg followed by cyclophosphamide (CY) 200 mg/kg, each administered over 4 days. He received an infusion of bone marrow containing 4 × 10 8 nucleated cells/kg recipient body weight (bw) from his HLA-identical, MLC-negative brother. Graft-versus-host disease (GVHD) prophylaxis was standard cyclosporin A (CsA). The post BMT course was not complicated by GVHD or infections.
Hematopoietic reconstitution was rapid. By day +11, the leukocyte count had increased to Ͼ1 × 10 9 /l with 50% neutrophils; hemoglobin level Ͼ9 g/dl became stable 6 weeks after transplantation. Platelet count increased to Ͼ50 × 10 9 /l on day +55. Fifty-seven days after the transplant the patient was discharged from hospital.
Full engraftment was demonstrated on day +88 by short tandem repeat (STR) polymorphism via PCR-based technology 10,11 on peripheral blood.
Calcium metabolism
From day +l5, serum calcium levels progressively increased and were maximal on day +29 (5.7 mEq/l) with a 24-h urine calcium excretion of 20 mEq. Therapy with methylprednisolone 0.5 mg/kg/day and hyperhydration were started, and serum calcium levels normalized within 2 months. No additional treatment was necessary. Analogously, a 24-h study of urinary calcium excretion revealed a steady increase with peak values on day +38 (32 mEq).
Follow-up and current status
A longitudinal series of skeletal radiographs after BMT showed progressive radiodensity reduction with marked metaphyseal remodeling. The liver and spleen decreased in size until they reached normal parameters. Bone biopsy specimens collected 18, 22 and 32 weeks post-BMT showed progressive resorption of trabeculae coupled with expansion of intramedullary hematopoietic activity and an increase in osteoclasts. Axial MRI of the optic canals showed progressive enlargement. Coronal MRI showed normal morphology of bone and bone marrow (Figure 1b) . Sixty months after transplant, the patient was in a satisfactory clinical condition with significant regression of his symptoms. Hemochromocytometric analysis produced normal values and serum calcium was within the normal range. The 99mTc sulphur colloid scan showed progressive development of intramedullary activity. No change in visual impairment was found as compared to pre-BMT conditions. Growth retardation was parallel to the percentile at the time of BMT; hormone pattern was normal, with a tendency towards normal puberty.
Case 2
Clinical characteristics
This patient was referred to our BMT Unit in October 1993 at the age of 4 years and 10 months with a diagnosis of osteopetrosis. Clinical characteristics at presentation and before BMT are summarized in Table 1 . At the time of our examination, skeletal radiographs showed typical findings of osteopetrosis (Figure 2a and b) and bone biopsy showed thickening of trabeculae and obliteration of medullary spaces with rare microfoci of hematopoiesis. Visual evaluation showed severe impairment due to bilateral optic nerve subatrophy. Nystagmus and abnormal response to afferent pupillary reflex were present. Visual evoked potential (VEP) confirmed the diagnosis of severe nerve compression. 12, 13 Axial MRI showed an increased signal intensity within the superior sagittal sinus because of slow venous flow caused by stenosis of the skull base foramina. Coronal MRI of the abdomen showed a low signal in all bone areas and in the bone marrow (Figure 3a) .
Bone Marrow Transplantation
The 99mTc-sulphur colloid scan showed almost complete absence of intramedullary hematopoiesis with 70% of the tracer uptake concentrated in the spleen.
On the basis of hematological and skeletal manifestations, metabolic balance and family history, we excluded, as in the previous case, a dominant form as well as a form due to CA II deficiency.
Bone marrow transplant
The patient was conditioned for BMT with Bu 16 mg/kg, followed by CY 200 mg/kg, each administered for 4 days, and thiotepa 5 mg/kg in a single dose. Two days later, he received an infusion of bone marrow containing 5.1 × 10 8 nucleated cells/kg recipient bw from his HLA-identical brother. GvHD prophylaxis included standard CsA. On day +18, the leukocyte count had increased to Ͼ1 × 10 9 /1 and on day +10 neutrophil count had increased to 0.5 × 10 9 /l. Platelet recovery was very slow and reached stable values of Ͼ50 × 10 9 /l after day +170. The post-BMT course was severely complicated on day +13 by grade III cutaneous GVHD, which persisted until after day +100 and evolved to a chronic form controlled by intensive immunosuppressive therapy. The patient was discharged from hospital 27 weeks after transplantation in a good clinical condition. Full engraftment was demonstrated on day +120 by STR polymorphism.
Calcium metabolism
Serum calcium levels increased progressively from day +9 and were maximal on day +15 (7.2 mEq/l). Initial treatment included methylprednisolone (40 mg/m 2 /day) and saline diuresis with furosemide boluses (1 mg/kg). The hypercalcemia persisted over the following 2 days and therapy with calcitonin and bisphosphonates was started and continued until day +30. Despite these measures, serum calcium levels remained above 6 mEq/dl for more than 10 days and returned to normal on day +39. Urinary excretion of calcium also steadily increased with peak values on day +15 (31.6 mEq/24 h). Serum calcium levels began to rise again from day +68 and previous therapy to control hypercalcemia was repeated until day +90.
Follow-up and current status
Longitudinal skeletal radiographs after BMT showed progressive radiodensity reduction (Figure 2c and d and Figure 3b ). The liver and spleen decreased in size until reaching normal parameters. Fourteen weeks after transplant, intramedullary hematopoietic cells and osteoclasts appeared in bone biopsy specimens. The 99mTc-sulphur colloid showed decreased splenic uptake as well as progressive development of intramedullary hematopoietic activity. Forty-eight months after BMT the child showed normal psychomotor development and was in a satisfactory clinical condition. No change in visual impairment was found as compared to pre-BMT conditions despite a complete remodeling of skeletal abnormalities. Growth was parallel to the percentile at the time of BMT. 
Discussion
These patients fit the picture of a mild variant of AR osteopetrosis. In both cases, a dominant pedigree and carbonic anhydrase deficiency have been excluded. Several therapeutic strategies have been implemented to increase hematopoietic function and to reduce bone sclerosis in AR osteopetrosis. Each of these therapies, such as steroids, ␥ interferon, hydroxyvitamin D 3 alone or in combination, has produced limited and transient improvement. [14] [15] [16] [17] The only curative therapy reported is allogeneic BMT. 18, 19 During the last 15 years, almost 100 BMTs for osteopetrosis have been reported. To our knowledge, this is the first article outlining the long-term outcome of transplantation in children with a mild variant of AR osteopetrosis. It confirms that, as in the malignant form, stable engraftment of healthy matched bone marrow after effective preparation may correct bone abnormalities and, if present, impaired hematopoiesis. Therefore, it may contribute to a better quality of life, even though it does not 'cure' other abnormalities, such as visual impairment, and it only stabilizes psychomotor develop- ment and body growth. In both our cases, engraftment was documented by STR polymorphism. Comparison of bone biopsies before and after BMT showed complete correction of the underlying defect. Serial radiographs revealed bone remodeling and new non-sclerotic bone formation. Psychomotor development was normal. After 4 and 5 years, respectively, growth was parallel to the percentile at the time of BMT. Some issues must be considered before attempting BMT for a child with osteopetrosis. Diagnosis must be made at a suitably early stage of the disease because visual impairment progresses constantly to blindness and is not corrected in cases where it is already present at the time of BMT. Other neurological manifestations of osteopetrosis may include strabismus, facial paralysis, deafness, trigeminal nerve involvement and anosmia. 17 Most of these result from direct compression of cranial nerves and are most pronounced in patients with early disease onset. 20 Both of our patients only showed severe visual impairment with bilateral optic nerve subatrophy, which stabilized after BMT. 21 Hypercalcemia requiring treatment with saline diuresis, diuretics, bisphosphonates, synthetic calcitriol or dyalison is an unusual complication that occurs in about 35% of patients 18 with osteopetrosis undergoing BMT. It may develop 10 to 60 days after BMT and it is more severe in older patients who have massive bony deposits of calcium, which is released with bone resorption following BMT. 21 Death from severe hypercalcemia refractory to intensive treatment has been reported. 18 Careful monitoring of calcium balance, together with the currently available drugs that selectively inhibit calcium resorption from bone, proBone Marrow Transplantation vide effective options for controlling this life-threatening complication.
In summary, BMT represents the only chance of curing children with a mild variant of AR osteopetrosis. 22 This procedure allows complete resolution of skeletal deformities and hepatosplenomegaly caused by extramedullary hematopoiesis. Visual impairment does not show any improvement with respect to pre-BMT conditions, which is why BMT is indicated before visual loss occurs when a matched sibling donor is available.
